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CD8 T cells are recognized key players in control of persistent virus infections, but increasing evidence suggests that
assistance from other immune mediators is also needed. Here, we investigated whether specific antibody responses
contribute to control of lymphocytic choriomeningitis virus (LCMV), a prototypic mouse model of systemic persistent
infection. Mice expressing transgenic B cell receptors of LCMV-unrelated specificity, and mice unable to produce
soluble immunoglobulin M (IgM) exhibited protracted viremia or failed to resolve LCMV. Virus control depended on
immunoglobulin class switch, but neither on complement cascades nor on Fc receptor c chain or Fc c receptor IIB.
Cessation of viremia concurred with the emergence of viral envelope-specific antibodies, rather than with neutralizing
serum activity, and even early nonneutralizing IgM impeded viral persistence. This important role for virus-specific
antibodies may be similarly underappreciated in other primarily T cell–controlled infections such as HIV and hepatitis C
virus, and we suggest this contribution of antibodies be given consideration in future strategies for vaccination and
immunotherapy.
Citation: Bergthaler A, Flatz L, Verschoor A, Hegazy AN, Holdener M, et al. (2009) Impaired antibody response causes persistence of prototypic T cell–contained virus. PLoS
Biol 7(4): e1000080. doi:10.1371/journal.pbio.1000080
Introduction
Infections associated with persistent viremia include
human immunodeﬁciency virus (HIV) and the hepatitis B
and C viruses (HBV, HCV), which affect more than 500
million people worldwide. However, available options to
prevent and treat particularly HIV and HCV are unsatis-
factory. To reﬁne existing strategies aimed at combating
these devastating epidemics, and to help direct future efforts,
a better understanding of the immune effector pathways
preventing viral persistence is of particular importance.
For almost a century, lymphocytic choriomeningitis virus
(LCMV) infection of mice has served as a primary model to
study basic mechanisms of the virus–host relationship in
persistent infection [1]. It has led to the discovery of several
essential concepts [2], including MHC restriction of T cells,
viral mutational escape from CD8 cytotoxic T cells (CTL),
CTL dysfunction in persistent infection and MHC linkage of
virus control. LCMV neutralizing antibody (nAb) responses
typically appear late and remain relatively weak [1]. Accord-
ingly, the key role of CTL in controlling and resolving
systemic persistent infections has initially been described for
LCMV [3–5] with subsequent extension of the concept to
important human pathogens such as HIV and HCV. Declining
viremia in HIV coincides with the appearance of antiviral
CD8 T cells [6,7], and the concept of CTL-mediated HIV
control was further strengthened by the association of
‘‘protective’’ HLA molecules with long-term nonprogression
in many so-called ‘‘elite controllers’’ [8]. In addition,
experimental depletion of CD8 T cells in simian immunode-
ﬁciency virus (SIV)-infected macaques also underlined the
importance of CTLs in the control of acute, as well as long-
term infection [9–11]. Analogous observations were made in
HBV- and HCV-infected monkeys [12,13].
Apart from the virtually undisputed contribution of CTLs,
evidence has accumulated to suggest that other mechanisms
of immune defense are also needed to contain or resolve
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PLoS BIOLOGYsystemic persistent virus infection. For instance, ‘‘protective’’
HLA alleles are also found in up to one third of individuals
with poor or undetectable immune control of HIV infection
[14,15], suggesting that even potent CD8 T cell responses are
insufﬁcient for HIV control. Conversely, many ‘‘elite con-
trollers’’ lack any of the known ‘‘protective’’ alleles [15].
Moreover, the recent failure of the CD8 T cell–based Merck
‘‘STEP’’ vaccine trial in human HIV infection has alerted the
community and has sparked renewed interest in comple-
mentary mechanisms that may aid immune defenses against
persistent viral disease [16].
Antibodies are among the obvious candidates to comple-
ment CTL-mediated control. However, their contribution to
the resolution of primary virus infections in general, and
persisting ones in particular, has remained controversial.
Rapid mutational escape of persisting viruses from antibody
neutralization represents a major obstacle to efﬁcient anti-
body-mediated control [17–21]. Moreover, observations that
patients with Bruton’s agammaglobulinemia can control
acute viral diseases [22] helped create a generally held notion
that, unlike what applies for protection against reinfection,
primary viral infections were predominantly controlled by
cell-mediated immunity [22]. Experiments in mice, monkeys,
and man had shown that passive administration of potent
nAbs or transgenic expression of a virus-neutralizing B cell
receptor (BCR) can prevent infection [23,24], augment virus
control during infection [25–27], or prevent the establish-
ment of persistence [28,29]. Still, these experimental obser-
v a t i o n sd i dn o tc h a l l e n g et h ea b o v ed o g m as i n c et h e
experimental conditions chosen did not mimic the kinetics
and magnitude of the host’s spontaneous nAb response
(delayed and weak).
Similarly, it seemed unlikely that antibodies could inﬂu-
ence LCMV control and persistence, until B cell–deﬁcient
mice were found to control the infection only transiently, or
not at all. B cell–deﬁcient mice showed vanishing CD8 T cell
function and viral recrudescence [30,31], but the conclusions
became doubtful when the mice were shown to have a
distorted splenic microarchitecture and intrinsically defec-
tive CD4 T cell responses [32–34]. As CD4 T cells are essential
to the maintenance of effective antiviral CD8 T cell responses
[35], the shortcomings in viral resistance were concluded to
result from defective T help, rather than from the lack of
antibody [34].
Given the outlined uncertainties, combined with the
importance of such fundamental knowledge in order to
reﬁne preventive and therapeutic strategies in humans, we
have readdressed the role of speciﬁc antibody responses to
the control and resolution of persistent infection. We used
the LCMV model to establish viral infection in genetically
engineered mice that support the development of B cells, but
do so only with restricted diversity and predominantly
LCMV-unrelated speciﬁcity. In addition, we infected B cell–
sufﬁcient mouse models, unable to mount either serum
immunoglobulin M (IgM) or immunoglobulin G (IgG)
responses. Our studies reveal that virus-speciﬁc antibodies,
including early adaptive IgM responses, play an essential role
in reducing viral loads and ultimately determine viral
clearance or persistence.
Results
B Cell Receptor Diversity Correlates with the Magnitude of
Antiviral Antibody Responses and Determines Efficacy of
Virus Control
Using the murine model of LCMV infection, we aimed here
at investigating the contribution of speciﬁc antibody to
prevent persistent infection. To overcome the limitations
intrinsic to B cell–deﬁcient mouse models (i.e., distorted
splenic microarchitecture with resulting defects in CD4 T cell
responses), we ﬁrst exploited two genetically engineered
mouse models with a severely narrowed, predeﬁned BCR
repertoire of LCMV-unrelated speciﬁcity. T11lMT [36] carry
an immunoglobulin (Ig) heavy chain transgene in an IgM
heavy chain–deﬁcient background, whereas VI10YEN [37]
combine an Ig light chain transgene with a knockin at the
endogenous Ig heavy chain locus. Both constructs render the
respective B cells speciﬁc for vesicular stomatitis virus (VSV)
that is antigenically unrelated to LCMV (for a more detailed
description of these strains, including their residual ability of
generating antibody repertoire diversity, see Text S1). Unlike
B cell–deﬁcient mice, these animals exhibited a normal
splenic microarchitecture in immunohistochemistry, and
mounted unimpaired CD4
þ T cell responses against LCMV,
as determined by intracellular staining of interferon c (IFNc)
upon peptide stimulation (Figure S1 and Text S1). We
infected B cell–deﬁcient lMT mice [38] (targeted deletion
of the IgM transmembrane domain), BCR-restricted T11lMT
and VI10YEN mice, and C57BL/6 control mice with 10
6
plaque-forming units (PFU) of LCMV intravenously (i.v.)
(Figure 1). Unlike C57BL/6 mice that resolved viremia within
12 d, T11lMT mice exhibiting the lowest degree of BCR
diversity failed to contain the infection and—like B cell–
deﬁcient lMT mice—remained viremic throughout the
observation period of 96 d (Figure 1A). Similar, albeit less-
pronounced, effects were seen in VI10YEN mice displaying a
more diverse BCR repertoire than T11lMT mice. Seven of
ten VI10YEN mice tested in three independent experiments
exhibited protracted viremia as compared to C57BL/6 wild-
type mice (Figure 1A and unpublished data). Even more
pronounced was the impact of BCR diversity on the control
of the more invasive Clone 13 strain of LCMV (Figure 1B).
Only C57BL/6 mice succeeded in resolving viremia, whereas
BCR-restricted VI10YEN and T11lMT mice, and B cell–
deﬁcient JHT [39] mice (targeted deletion of the immuno-
globulin JH locus; JHT and lMT mice were used likewise in
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Author Summary
Persistent viruses such as hepatitis C virus (HCV) or HIV can defeat
the body’s defense system and cause devastating epidemics
worldwide. Recent attempts at vaccinating against HIV have relied
on the induction of specific antiviral killer T lymphocytes but have
failed to confer protection on the host. Better knowledge about how
a successful defense should operate is therefore essential for
developing and refining new vaccines. Here, we have used a
prototypic mouse model to investigate basic defense mechanisms
required to eliminate persisting viruses. Experiments in several
genetically engineered mouse models show that contrary to
common belief, not only antiviral killer T cells, but also antibodies
(produced by B cells), are needed to prevent a virus from persisting
in its host. These findings suggest that induction of antibodies,
along with antiviral killer T lymphocytes, should be envisaged when
devising new strategies for vaccinating against HIV or HCV.this study) remained viremic throughout the observation
period of 123 d. Thus, BCR diversity was essential for efﬁcient
resolution of LCMV infection. Further support for this
notion came from experiments in ‘‘quasimonoclonal’’ (QM)
mice [40] with a predeﬁned nitrophenyl-speciﬁc B cell
repertoire owing to knockin of a rearranged immunoglobulin
heavy chain gene in combination with an immunoglobulin
light chain transgene (Figure S2). Interestingly also, the
requirements for BCR diversity became apparently more
stringent as the infection was prone to persistence. That is,
VI10YEN mice were able to clear LCMV strain WE (LCMV-
WE), albeit with some delay, but they failed at resolving
chronic infection with LCMV strain Clone 13. The above
patterns of virus control or persistence correlated only to a
limited extent with the ability of the respective mouse strains
to mount a late virus-neutralizing antibody response (Figure
1C and 1D). In LCMV Clone 13 infection, the appearance of
neutralizing serum activity around day 45 after infection
coincided with viral clearance. In contrast, a clear rise in
LCMV-WE-nAb occurred only between 50 and 74 d after
infection, i.e., more than 1 mo after viral clearance from the
blood. In C57BL/6 mice, this response was consistently
measured although the titers varied considerably between
individual animals. With further delay and barely above the
detection limit of our assays, nAbs were also measured in
some VI10YEN mice (Figure 1C, not statistically signiﬁcant),
providing only partial correlation with this mouse strain’s
ability to control LCMV-WE infection. In contrast, nAbs
always remained below detection levels in viremic T11lMT
mice. The lack of temporal association, at least in LCMV-WE
infection, between the appearance of nAb and clearance,
prompted us to study nonneutralizing antibody (non-nAb)
responses. The glycoprotein (GP) is the only surface
determinant on LCMV particles. It is synthesized as a
Figure 1. Viral Clearance or Persistence Depends on BCR Repertoire Diversity and Correlates with Antiviral Antibody Formation
B cell–deficient (lMT in [A, C, and E]; JHT in [B and D]), BCR-restricted T11lMT and VI10YEN mice, and control C57BL/6 mice were infected i.v. with 10
6
PFU of LCMV-WE (A, C, and E) or 10
6 PFU of LCMV Clone 13 (B and D).
(A and B) Infectious virus in blood was monitored over time. Numbers next to the VI10YEN curve in (A) indicate viremic VI10YEN mice per number of
mice tested at each time point. Comparison of viral clearance kinetics (combined analysis of up to three experiments): LCMV-WE (A) C57BL/6 versus all
other groups, VI10YEN versus T11lMT, VI10YEN versus lMT, p , 0.01. LCMV Clone 13 (B) C57BL/6 versus all other groups p , 0.05. All other
comparisons p . 0.05.
(C and D) nAbs were monitored over time. Double asterisks (**) indicate p , 0.01.
(E) LCMV-WE-GP1–specific IgG was measured by ELISA. Symbols represent the mean 6 SEM of four mice per group. A single asterisk (*) indicates p ,
0.05, and double asterisks (**) indicate p , 0.01.
For (A and C), one representative experiment of three similar experiments is shown. (E) displays one of two experiments, with symbols representing the
mean 6 SEM of three to five mice per group.
doi:10.1371/journal.pbio.1000080.g001
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Antibodies Decide Viral Persistenceprecursor protein and is posttranslationally cleaved into GP1
and GP2 subunits that remain noncovalently associated [41].
GP1 makes up an outer globular domain, whereas GP2 forms
a membrane-anchored stalk [41]. Hence, GP1 is accessible on
the infectious virion surface, rendering this antibody specif-
icity of particular interest. Here, we exploited recently
developed ELISA techniques [42] for measuring LCMV-WE
GP1-speciﬁc antibodies. By day 12 after infection, LCMV-WE
evoked a GP1-speciﬁc IgG response in C57BL/6 mice and at
lower titers also in V10YEN mice, but not in T11lMT mice,
correlating with virus control (Figure 1E, B cell–deﬁcient
lMT mice shown as negative controls). Thus, the timing of the
GP1-binding antibody response as well as the differential
magnitude in C57BL/6, VI10YEN and T11lMT mice matched
best the pattern of virus clearance.
Both Adaptive IgM and IgG Are Needed for Efficient Virus
Control
Next, we assessed the individual contribution of IgM and
IgG responses to virus control. All monoclonal LCMV nAbs
characterized today are of an IgG isotype, and so is the late
nAb response observed in the course of natural infection [27].
Hence, any potential role of antibodies in resolution of
LCMV infection had previously been accredited to IgG. To
test for the role of class switch-dependent isotypes including
IgG, we used gene-targeted mice lacking activation-induced
cytidine deaminase (AID
 / ) [43]. AID
 /  mice are unable to
undergo class-switch recombination and somatic hypermuta-
tion, and in our experiments, could not resolve LCMV-WE
infection during the observation period of 96 d (Figure 2A).
As expected, AID
 /  mice displayed a complete absence of
nAbs and GP1-speciﬁc serum IgG (Figure 2C and 2E),
suggesting that immunoglobulin class-switch recombination
and IgG production together with somatic hypermutation are
essential steps in the resolution of LCMV infection.
To assess a potential role of IgM antibodies we exploited
the sIgM
 /  mouse model [44]. sIgM
 /  B cells express IgM as
their surface receptor and secrete IgG upon class-switch
recombination but are unable to secrete the early IgM
isotype. Experiments were carried out to conﬁrm that
according to expectations and unlike B cell–deﬁcient lMT
mice, B cell–competent sIgM
 /  mice display a normal
lymphoid microarchitecture and mount unimpaired CD4
þ T
cell responses (Figure S3). Surprisingly, however, LCMV-WE
infection resulted in substantially prolonged viremia in
Figure 2. Virus Control Requires Secreted IgM and Also AID-Dependent Class-Switch Recombination and Affinity Maturation
(A–E) Mice of the indicated genotypes were infected with 10
6 PFU of LCMV-WE (A, C, and E) or Clone 13 (B and D) i.v. Viremia (A and B), nAbs (C and D),
and LCMV-WE-GP1–binding antibodies (E) were monitored over time. Symbols represent the mean 6 SEM of three to four (A, C, and E) or nine to ten (B
and D) mice per group. Comparison of viral clearance kinetics: LCMV-WE (A): C57BL/6 versus all other groups, sIgM
 / versus AID
 / , sIgM
 / versus JHT,
p , 0.05. LCMV Clone 13 (B): C57BL/6 versus sIgM
 / p , 0.01, as indicated by double asterisks (**). All other comparisons p . 0.05. n.s., not significant.
doi:10.1371/journal.pbio.1000080.g002
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 /  mice as compared to C57BL/6 control mice (Figure
2A), suggesting that contrary to expectations, an antibody
response of IgM isotype contributed to virus control. More
strikingly even, nine of ten sIgM
 /  mice failed to resolve
LCMV Clone 13 infection for a period of at least 100 d,
whereas all nine C57BL/6 mice had cleared viremia within 42
d after infection (Figure 2B and unpublished data).
The analysis of nAb responses (measuring both IgM and
IgG, Figure 2C and 2D), conﬁrmed that the kinetics and
magnitude of the nAb response were indistinguishable in
sIgM
 /  and C57BL/6 controls, and therefore, likely were of
IgG isotype as previously reported. As expected, also LCMV-
WE-GP1–binding IgG responses showed normal kinetics in
sIgM
 /  mice. Somewhat higher GP1-speciﬁc IgG peak titers
in sIgM
 /  mice as compared to C57BL/6 control mice were
likely the result of prolonged viremia with an increased
antigen burden (Figure 2E). In support of this notion,
differences in antibody titers became particularly apparent
between day 12 and 20 when C57BL/6, but not sIgM
 / , mice
had cleared the infection. The above experiments had
suggested that differences in virus loads of sIgM
 /  and
C57BL/6 mice were manifest as early as 1 wk after infection (p
, 0.01 for LCMV Clone 13, Figure 2B). Additional experi-
ments corroborated this difference in early virus loads also
for LCMV-WE infection (Figure 3A, p , 0.01). As a likely
mediator of this difference, ELISA assays detected GP1-
speciﬁc IgM responses in day 8 LCMV-WE–infected C57BL/6,
but not sIgM
 / , mice (Figure 3B), antibodies that were absent
from naive C57BL/6 mouse serum (Figure 3B). Importantly
also, the GP1-speciﬁc IgM responses measured here were
conﬁrmed to be entirely antigen-speciﬁc since total serum
IgM (Figure 3C), unlike serum IgG [45], remained largely
unaltered after LCMV infection. A time-course analysis
revealed that GP1-speciﬁc IgM was highest on day 4 and 7
after infection, followed by a continuous decline of this
isotype concomitant with class switch and appearance of
GP1-speciﬁc IgG (Figure 3D). These assays were, however,
performed with unseparated serum, and competition be-
tween IgG and IgM in ELISA may have resulted in an
underestimation of IgM levels at later time points.
Figure 3. Early Adaptive IgM Response Rather Than Natural Antibodies Contributes to Virus Control
(A–C) sIgM
 / and C57BL/6 control mice were infected with 10
6 PFU of LCMV-WE i.v. Viremia (A), LCMV-WE-GP1–specific IgM (B), and total serum IgM (C)
were determined 8 d later. Bars represent the mean 6 SEM of five to ten mice per group.
(D) C57BL/6 mice were infected with 10
6 PFU of LCMV-WE i.v. LCMV-WE-GP1–specific IgM and IgG were measured over time. Symbols represent the
mean 6 SEM of four mice per group.
(E and F) sIgM
 / mice were substituted i.p. with 2 ml of naive C57BL/6 serum on day 1. Control groups consisted of sIgM
 / and C57BL/6 mice without
serum substitution. All mice were infected with 10
6 PFU of LCMV-WE i.v. on day 0. Total serum IgM was measured on the day of virus challenge (E), and
viremia was determined on day 21 (F). Bars represent the mean 6 SEM of five to twelve animals.
A single asterisk (*) indicates p , 0.05, and double asterisks (**) indicate p , 0.01. n.s., not significant.
doi:10.1371/journal.pbio.1000080.g003
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 /  mice not only lack adaptive IgM responses but also
natural IgM, which contributes to control of other viral
infections [46]. For dissecting the role of preexisting natural
antibodies, we reconstituted sIgM
 /  mice with naive C57BL/6
mouse serum (Figure 3E). Despite reaching total serum IgM
levels at least equivalent to normal C57BL/6 mice, recon-
stitution of natural IgM in sIgM
 /  mice failed to restore virus
control (Figure 3F). Taken together, these data demonstrated
that adaptive IgM as well as IgG responses both played
essential roles in the efﬁcient resolution of LCMV infection.
Interestingly, unaltered nAb kinetics in sIgM
 /  and C57BL/6
control mice suggested that antiviral IgM mediated its effects
by mechanisms other than classical virus neutralization.
Antibody Therapy Prevents Viral Persistence and
Preserves CTL Function in T11lMT Mice
Next, we studied whether antibody therapy could restore
virus control in BCR-restricted LCMV noncontroller mice.
For this purpose, we infected T11lMT mice with LCMV-WE
and treated them on day 4 and day 7 with either normal
serum (negative control) or with normal serum reconstituted
with GP1-speciﬁc monoclonal antibody (Figure 4A). T11lMT
mice treated with GP1-speciﬁc antibody eliminated LCMV as
efﬁciently as did C57BL/6 wild-type mice, whereas control-
treated T11lMT mice remained viremic, as expected (com-
pare Figure 1A). The same antibody treatment that was
successful in T11lMT mice failed, however, to exert a
detectable effect on virus loads when administered to
TCRb
 / d
 /  mice [47] lacking T cells owing to homozygous
deletion of the T cell receptor b and d chain loci (Figure 4B).
These data were compatible with the interpretation that T
cells of T11lMT mice could control LCMV infection if
appropriately aided by speciﬁc antibodies, whereas neither T
cells nor antibody therapy was sufﬁcient to control LCMV on
its own.
Exhaustion of CD8 T cell responses as a result of continued
antigen exposure is a common observation in persistent viral
infection [48,49]. Hence, we investigated whether antibody
therapy could prevent CD8 T cell exhaustion in T11lMT
mice. The initial LCMV-speciﬁc CD8 T cell response of
T11lMT mice not only was of normal frequency and was
functional in terms of IFNc secretion (Figure S1D) but also
displayed an unimpaired capacity for killing antigenic cells in
vivo, irrespective of antibody treatment (Figure 4C). Of note,
virus loads were still similar in all groups when these tests
were performed on day 7 (Figure 4D). On the contrary,
defective cytolytic activity was observed in control-treated
T11lMT mice on day 35 during the chronic phase of
infection. Prevention of viral persistence by antibody therapy
(Figure 4F) restored in vivo cytotoxicity of T11lMT mice to
normal levels on day 35 (Figure 4E). This lent further support
to the interpretation that the CD8 T cell response of T11lMT
mice was intrinsically normal, and that its decline during
chronic infection was merely the result of viral persistence
rather than the cause thereof. Albeit less likely, a subtle
intrinsic CD8 T cell deﬁciency of T11lMT mice cannot,
however, be formally excluded. Irrespective thereof, antibody
therapy may help preserve the antiviral CD8 T cell response.
Unimpaired Virus Clearance in the Absence of the
Classical and Alternative Complement Cascades, of the Fc
Receptor c Chain or of Fc c Receptor IIB
To evaluate the role of the classical and alternative
complement cascades as major effector pathways of anti-
body-mediated immunity, we studied clearance of LCMV-WE
in mice lacking complement components C3 and C4
Figure 4. Antibody Therapy Prevents Viral Persistence and Preserves CTL
Function in T11lMT Mice
(A and B) Mice of the indicated genotypes were infected with 10
6 PFU of
LCMV WE. On day 4 and day 7 (arrows), they were treated with GP1-
specific antibody in normal serum or with normal serum only (control), as
outlined in the chart. Viremia was monitored over time. Symbols
represent the mean 6 SEM of four to five mice per group. The data in (A
and B) originate from the same experiment, and the identical C57BL/6
group is shown in both graphs. Virus clearance kinetics in C57BL/6 mice
and anti-GP1 antibody-treated T11lMT mice were indistinguishable (p .
0.05), but each one of them differed significantly from the remaining
three groups (p , 0.01). All other comparisons p . 0.05.
(C–F) C57BL/6 and T11lMT mice were treated as in (A and B). On day 7 (C
and D) and day 35 (E and F) after infection, virus-specific cytotoxic
activity of CD8
þ T cells was measured in an in vivo CTL assay (C and E),
and virus loads were determined in blood (D and F). Bars represent the
mean 6 SEM of three to five mice per group. Double asterisks (**)
indicate p , 0.01. n.s., not significant.
doi:10.1371/journal.pbio.1000080.g004
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 / C4
 /  mice; see Materials and Methods). C3
 / C4
 /  mice
resolved viremia as efﬁciently as wild-type control mice
(Figure 5A), whereas B cell–deﬁcient JHT control mice
remained viremic throughout. An analogous experiment
was carried out in mice lacking Fc c receptors I, III, and IV
owing to deletion of the common c chain (FcRc
 /  [50]).
FcRc
 /  mice cleared LCMV-WE infection as efﬁciently as did
C57BL/6 wild-type mice, whereas B cell–deﬁcient JHT and
T11lMT mice both showed unchecked viremia throughout
the observation period (Figure 5B). Unlike Fc c receptors I,
III, and IV, Fc c receptor IIB (FccRIIB) expression does not
depend on the common c chain. To study the contribution of
this receptor, we infected FccRIIB -deﬁcient mice (FccRIIB
 / ;
see Materials and Methods) with LCMV, but found unim-
paired virus control (Figure 5C). Taken together, these data
excluded an essential individual contribution of classical and
alternative complement cascades, of Fc c receptors I, III, and
IV, and of FccRIIB, respectively, in mediating protective
antibody effects in the natural course of LCMV infection.
Discussion
The present data show that virus-speciﬁc antibody
responses, including early IgM, play an unexpected key role
in preventing viral chronicity in the CTL-controlled murine
model of LCMV infection. These observations are compatible
with the rapid escape from antibody recognition seen in
other primarily CTL-controlled infections, including HIV
and HCV [19–21], and indicate that speciﬁc antibody
responses represent a level of antiviral pressure that tends
to be underappreciated.
The observed antiviral effects can only be partially
accredited to antibody-mediated virus neutralization. Albeit
clearance of LCMV Clone 13 in C57BL/6 mice did coincide
with the appearance of nAbs (compare Figure 2B and 2D),
IgM effects on LCMV Clone 13 and LCMV-WE titers were
evident already on day 7/8 after infection (Figures 2A, 2B, and
3A) at a time when nAbs were undetectable even if using
virtually undiluted serum for the assays (unpublished data).
Similarly, LCMV-WE was cleared weeks before nAbs could be
detected (compare Figure 2A and 2C). Obviously, ‘‘absence of
proof’’ for early nAb does not equate ‘‘proof of absence,’’ and
we recognize that ‘‘nAb consumption’’ during viremia or
subsequent phases of protracted clearance from tissues [51]
would provide an explanation for our inability to detect
nAbs. However, we favor the idea that the delay in LCMV nAb
detection, relative to the antiviral effects observed, rather
results from the need for time-intensive afﬁnity maturation
[42].
The protective capacity of nAbs is classically explained by
‘‘virion occupancy,’’ i.e., sterical hindrance interfering with
cell-surface receptor binding [52]. Non-nAbs, on the other
hand, may mediate protection via a number of mechanisms,
including: (1) virion occupancy by complement C1q binding
to a virion-bound antibody [53], (2) complement cascade
activation, leading to further virion occupancy through
covalent opsonization, (3) complement-mediated virion lysis,
(4) Fc-receptor–mediated virion phagocytosis and destruc-
tion, (5) Fc-receptor–mediated stimulation of the innate
immune system, (6) immune complex formation and resulting
modiﬁcation of tissue distribution and cellular tropism, (7)
antibody-dependent cellular cytotoxicity (ADCC), via anti-
body binding to viral surface proteins on infected cells, (8)
impaired virus production, through antibody-mediated cross-
linking of cell surface–expressed viral envelope protein [54],
or (9) destruction of target protein or host cells, through
antibody-mediated reactive oxygen catalysis [55]. Although a
full assessment of the individual contribution of each of these
potential pathways lies outside the scope and intention of the
present study, we do present data ruling out a major
individual contribution for covalent complement opsoniza-
tion and lysis, mediated through C3 and/or C4 activation, as
well as for FcRc- and FccRIIB-facilitated mechanisms [50,56]
(Figure 5). It remains possible that another mechanism not
yet experimentally addressed here may account for most of
Figure 5. Efficient Virus Clearance Occurs in the Absence of Either
Complement, Fc Receptor c Chain, or FccRIIB
Mice of the indicated genotypes were infected with 10
6 PFU of LCMV-
WE, and viremia was monitored over time. Symbols represent the mean
6 SEM of three to four mice per group. (A–C) represent independent
experiments. C3
 / C4
 /  mice were tested alongside the experimental
groups displayed in Figure 2A, 2B, and 2C, and hence the identical
C57BL/6 and JHT control groups are shown in Figure 2A and (A).
Comparison of viral clearance kinetics: (A) C57BL/6 versus C3
 / C4
 / p .
0.05 (not significant); C57BL/6 versus JHT, C3
 / C4
 /  versus JHT p ,
0.05. (B) C57BL/6 versus FcRc
 / , JHT versus T11lMT p . 0.05 (not
significant); C57BL/6 versus JHT, C57BL/6 versus T11lMT, FcRc
 /  versus
T11lMT, FcRc
 /  versus JHT, p , 0.05. (C) C57BL/6 versus FccRIIB
 /  p .
0.05 (not significant).
doi:10.1371/journal.pbio.1000080.g005
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clearance [57] could explain the observed IgM effects (Figures
2A, 2B, and 3A). However, substantial redundancy in these
multiple mechanisms may render it difﬁcult to work out the
contribution of individual mechanisms including the ones we
have tested here, i.e., in the absence of a speciﬁc pathway,
compensation by the remaining ones may sufﬁce for virus
clearance.
The present ﬁndings are of considerable importance for
our understanding of virus–host relationship in persistent
infection and for reﬁning preventive and therapeutic
strategies: The success of antibody therapy in T11lMT mice,
but not in TCRb
 / d
 /  animals (Figure 4A and 4B), suggests a
synergistic effect of cellular and humoral immune defense, at
least for LCMV. Antibody therapy can apparently help
preserve T cell function, and hence early administration
may be most promising. Albeit our experimental therapy was
administered during a phase of infection in which IgM
predominates (compare Figure 3D), IgG was efﬁcient. This
may be of practical importance since both vaccination and
immunotherapy typically rely on IgG rather than on IgM.
Owing to structural reasons, potent nAb responses against
persisting viruses are generally difﬁcult to elicit through
vaccination [20,58], but non-nAbs represent an attainable
goal. The present data from LCMV infection in mice strongly
suggest that non-nAbs, alongside antiviral CTL responses and
nAbs, can determine clearance or persistence. We suggest
that non-nAbs operate by blunting the infection and thereby
strengthening the efﬁcacy of other immune mediators such as
CTLs and nAbs, but also NK cells [59,60]. In the context of the
cited literature, our data support the idea that antibodies
should be considered anew in vaccination strategies aimed at
combating persistent viral disease, and that aside from nAbs
as a vaccine goal, non-nAbs also should be induced and
assessed.
It has recently been shown that non-nAbs speciﬁc for
LCMV GP-1 can mediate protective effects when expressed in
a transgenic context [27]. In nontransgenic wild-type mice, we
now show that virus-speciﬁc antibody responses, including
GP-1–binding IgM, are not only generated rapidly (see also
Figure 2G), but also exert signiﬁcant antiviral pressure
(compare Figure 2B and 2F; p , 0.01) in the days before
nAbs become detectable. Although we focused in our assays
on GP-1 binding antibodies, it remains entirely possible that
additional non-nAbs of alternative speciﬁcities may also
contribute to the observed protective effects. Deﬁning
characteristics and speciﬁcities of ‘‘protective’’ and ‘‘non-
protective’’ non-nAbs may therefore represent an important
next step in the direction of exploiting the protective
capacity of non-nAbs for vaccination and immunotherapy.
Failure of the HIV AIDSVax trial eliciting mostly non-nAbs
in the absence of cell-mediated immunity has somewhat
dampened the hope that non-nAbs could help containing
persistent infections [61,62]. Albeit non-nAbs are apparently
unable to protect on their own, studies have correlated ADCC
with HIV nonprogression, suggesting that non-nAbs may
indeed contribute to long-term control of HIV [63]. However,
much remains unclear about the overall importance of non-
nAbs, and antibodies in general, to the natural course of HIV
infection [64]. Moreover, the available data emphasize that
the mechanisms of antibody-mediated protection do not
always follow the traditional way of thinking. For instance,
even a broadly HIV-neutralizing monoclonal antibody was
shown to protect primarily via Fc-receptor–dependent
mechanisms [65]. Of note in this context, the HIV envelope
displays defective glycoproteins in great abundance [66].
Albeit unable to mediate cell entry, such defective glycopro-
teins are highly immunogenic and may represent efﬁcient
targets for non-nAbs. Of further importance here, non-nAbs
have a relatively broad spectrum of activity against both
autologous and heterologous HIV strains [67].
Taken together, the results from this study show that CD8 T
cells, even if ﬁrmly established as the predominant mecha-
nism of antiviral immune defense, need support from speciﬁc
antibodies to prevail and prevent viral persistence. Given the
relative ease of induction of non-nAbs (relative to nAbs),
combined with the observed protective effects, our ﬁndings
may provide new impetus for inclusion of antibody targets in
vaccines against persistent viral diseases.
Materials and Methods
Mice and animal experiments. C57BL/6 wild-type mice, lMT
 / 
[38], JHT
 /  [39], T11lMT [36], VI10YEN [37], QM [40], AID
 /  [43],
sIgM
 /  [44], C3
 / C4
 /  double-deﬁcient mice (a crossbreed of C3
 / 
[68] and C4
 / [69] mice), TCRb
 / d
 / [47], and FcRc
 / [50] were bred
at the Institute of Laboratory Animal Science, University of Zurich,
and were housed under speciﬁc pathogen-free (SPF) conditions
throughout. FccRIIB
 /  mice on a pure C57BL/6 background, in
which exons 4 and 5, encoding the ligand-binding EC2 and
transmembrane (TM) region, have been deleted by gene targeting
in Bruce4 ES cells (C57BL/6 background), were generated in the
laboratory of Sjef Verbeek. Absence of functional FccRIIB was
conﬁrmed both in functional in vivo and in vitro assays and at the
protein level, as will be described elsewhere in more detail. Experi-
ments with FccRIIB
 /  mice and controls were performed in a
conventional mouse facility. Animal experiments were carried out at
the University of Geneva and the University of Zurich with author-
ization by the respective cantonal authorities and in accordance with
the Swiss law for animal protection.
Viruses, infection, and antibody therapy. LCMV-WE was originally
obtained from F. Lehmann-Grube (Heinrich-Pette Institut, Hamburg,
Germany) and was propagated on L929 cells. LCMV Clone 13 was
obtained originally from R. Ahmed (Emory University, Atlanta,
Georgia, United States) and was grown on BHK-21 cells. Infections
were performed at a standard dose of 10
6 PFU by the intravenous
route. For therapy of T11lMT and TCRb
 / d
 /  mice, GP1-speciﬁc
monoclonal antibody KL25 [70] was administered intraperitoneally
on day 4 (100 lg) and on day 7 (1 mg), reconstituted in 400 llo f
normal (nonimmunized and uninfected) C57BL/6 serum. Control
animals were given 400 ll of normal serum.
Virus titration and detection of LCMV-neutralizing antibodies.
LCMV virus stocks and blood samples were titrated by standard
immunofocus assays on MC57G cells [71]. nAbs against LCMV-WE
and LCMV Clone13 were measured in an immunofocus reduction
assay using the respective homologous virus as described [58].
Enzyme-linked immunosorbent assays (ELISA). GP1-speciﬁc IgM
and IgG responses were measured by ELISA using a GP1-Fc fusion
construct produced in an eukaryotic system as described [42]. In the
GP1-Fc construct, amino acids 1–265 (i.e., the GP1 domain [42]) of the
LCMV-WE glycoprotein gene are fused to human Fc. As sole
modiﬁcation to the published method, anti-mouse IgM monoclonal
antibody coupled to HRP (Sigma) was used instead of anti-mouse IgG
when detecting GP1-speciﬁc IgM. Total serum IgM titers were
measured in ELISA as described previously [45]. Titers displayed
represent the serum dilution yielding twice background optical
density values.
Enumeration of epitope-speciﬁc T cell populations and in vivo CTL
assay. Single-cell suspensions of splenocytes were used for intra-
cellular cytokine assays as described [72]. Restimulation of virus-
speciﬁc cells was performed for 5–6 h in the presence of the following
synthetic peptides at 10
 6 M concentration: KAVYNFATC (GP33,
CD8
þ T cells), GPDIYKGVYQFKSVEFD (GP64, CD4
þ T cells), and
SGEGWPYIACRTSVVGRAWE (NP309, CD4
þ T cells).
Cytotoxic activity of CD8
þ T cells was measured in an in vivo CTL
assay as previously described [73]. In brief, syngeneic C57BL/6
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diacetate succinimidyl ester (CFSE) at two different concentrations
(CFSE
high or CFSE
low). In addition, CFSE
high cells were pulsed with
GP33 peptide at 10
 6 M concentration for recognition by antiviral
CTLs. 3310
7 cells of each population were cotransferred into virus-
infected recipient mice and into naive C57BL/6 mice (control). Five
hours later, the percentage of CFSE
high and CFSE
low donor cells in
peripheral blood mononuclear cells was determined by ﬂow
cytometry. Speciﬁc killing was calculated as: 100   ([(% CFSE
high in
test animal / % CFSE
low in test animal) / (% CFSE
high in naive / %
CFSE
low in naive)] 3 100).
Immunohistochemistry. Histological analyses were performed on
snap-frozen tissue. Sections were stained with rat monoclonal
antibodies against murine B220 (Pharmingen), F4/80, MOMA1, and
ERTR9 (all from BMA Biomedicals). Bound antibody was detected
using a goat anti-rat antibody (Caltag Laboratories) and an alkaline
phosphatase–coupled donkey anti-goat antibody (Jackson ImmunoR-
esearch Laboratories) with naphthol AS-BI (6-bromo-2-hydroxy-3-
naphtholic acid 2-methoxy anilide) phosphate and new fuchsin as a
substrate. The sections were counterstained with hemalum. For
tissues of VI10YEN mice carrying a light-chain transgene with rat
constant domains, reaction of anti-rat monoclonal antibody with the
transgenic light chain was prevented by using an alkaline phosphatase
conjugated Fc c fragment–speciﬁc goat anti-rat IgG antibody as a
secondary antibody (Jackson ImmunoResearch Laboratories).
Statistical analysis. One-way analysis of variance (ANOVA) with the
Least Signiﬁcant Difference (LSD) post test was used for the
comparison of individual values from multiple groups. Two-way
ANOVA was performed to compare antibody responses over time.
ANOVA was performed with SPSS version 13.0. Differences in
individual values between two groups were analyzed by t-tests
(unpaired, two-tailed), and virus clearance kinetics were compared
in log-rank tests using GraphPad Prism software vs. 4.0b. Viral titers
were log-transformed for statistical analysis, and viral clearance
kinetics were compared in a Kaplan-Meier format. p-Values , 0.05
were considered statistically signiﬁcant; p-values , 0.01 were
considered highly signiﬁcant.
Supporting Information
Figure S1. Normal Splenic Microarchitecture and Unimpaired CD4
þ
and CD8
þ T Cell Responses in T11lMT and VI10YEN Mice
(A) Histological spleen sections of lMT, VI10YEN, T11lMT, and
C57BL/6 control mice were stained for B220 (B cells), F4/80 (red pulp
macrophages), ERTR9 (marginal zone macrophages), or MOMA-1
(metallophilic marginal zone macrophages) as indicated. Each image
displays a representative area of spleen from three age-matched mice
per group analyzed. Magniﬁcation bars indicate 200 lm.
(B): Mice of the indicated genotypes were infected with 10
6 PFU of
LCMV-WE i.v. Eight days later, epitope-speciﬁc CD4
þ (GP64 and
NP309) and CD8
þ (GP33) T cell frequencies in spleen were
determined in an intracellular cytokine assay. Bars represent the
mean 6 the standard error of the mean (SEM) of three (GP64, NP309)
or three to eight animals (GP33) per group.
Found at doi:10.1371/journal.pbio.1000080.sg001 (4.6 MB TIF).
Figure S2. Delayed Virus Clearance in Quasimonoclonal (QM) Mice
Mice of the indicated genotypes were infected with 10
6 PFU of
LCMV-WE. Viremia (A) and nAbs (B) were monitored over time.
Symbols represent the mean 6 SEM of two to ﬁve mice per group.
One representative experiment of two similar ones is shown.
Comparison of viral clearance kinetics (combined analysis of two
experiments): QM versus C57BL/6, QM versus T11lMT, C57BL/6
versus T11lMT p , 0.01.
Found at doi:10.1371/journal.pbio.1000080.sg002 (453 KB EPS).
Figure S3. Normal Splenic Microarchitecture and Unimpaired CD4
þ
and CD8
þ T Cell Responses in sIgM
 /  Mice
(A) Histological spleen sections of sIgM
 /  were stained for B220 (B
cells), F4/80 (red pulp macrophages), ERTR9 (marginal zone macro-
phages), or MOMA-1 (metallophilic marginal zone macrophages) as
indicated. Sections of lMT and C57BL/6 mice are shown for
comparison (same panels as in Figure S1A). Each image displays a
representative area of spleen from three age-matched mice per group
analyzed. Magniﬁcation bars indicate 200 lm.
(B) sIgM
 /  and C57BL/6 control mice were infected with 10
6 PFU of
LCMV-WE i.v. Eight days later, epitope-speciﬁc CD4
þ (GP64 and
NP309) and CD8
þ (GP33) T cell frequencies were determined in an
intracellular cytokine assay. Bars represent the mean 6 SEM of three
mice per group.
Found at doi:10.1371/journal.pbio.1000080.sg003 (5.9 MB TIF).
Text S1. Normal Splenic Microarchitecture and Unimpaired CD4þT
Cell Responses in Mice with Restricted B Cell Receptor Diversity
Found at doi:10.1371/journal.pbio.1000080.sd001 (65 KB DOC).
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